Open Orphan plc
Open Orphan plc

Open Orphan plc share price, company news, analysis and interviews

Open Orphan plc (LON: ORPH) was a rapidly growing niche CRO pharmaceutical services company which was a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.

Open Orphan comprosed of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences.

Open Orphan now trades on the London Stock Exchange as hVIVO plc

hVIVO

hVIVO is the world leader in the testing of vaccines and antivirals using human challenge study models. It is a trusted partner and industry-leading clinical development services business pioneering human disease models based upon viral challenge.

Run from Europe’s only 24-bedroom quarantine clinic with onsite virology lab in London, hVIVO use human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious disease.

hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics.  Click here to view the hVIVO company profile.

Open Orphan

Venn Life Sciences

Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise, clinical trial design and execution services. This enables us to create, plan and execute drug and medical device development programs effectively and seamlessly for our clients. 

Venn has teams across both early and late phase research, late phase teams specialise in multi-site cross cultural clinical trials with unique knowledge of local and EU regulations. Over Venn’s 25 year history we have built up substantial therapeutic and study experience, contributing to the efficient management of sites, budgets and communication channels with all parties involved. Venn is renowned for its hands-on approach and consistent delivery of high quality work on time and on budget.

Open Orphan

Below you will find the 5 day trade history, latest news, interviews and Open Orphan share price.

Don't miss out --->

Receive this company's news, reports, interviews in your inbox, as we post it.

We don’t spam! Read our privacy policy for more info.

Share this page

Open Orphan plc

Open Orphan plc share price

Fundamentals

52 Week High / Low

News

hVIVO plc

Open Orphan name change to hVIVO plc now effective

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that further to its announcement on the 8th September 2022, the Company’s change of name to hVIVO plc (LON:HVO) has now been completed and is expected to take effect on AIM and Euronext Growth from 8.00 am tomorrow. The Company’s ticker will be HVO and the website address (including the investor relations content and the information required by AIM Rule 26 and Euronext Growth Rule 3.4) will be available at www.hvivo.com. The Company’s ISIN (GB00B9275X97) and

hVIVO plc

Open Orphan to hold a Capital Markets Day on 2 November 2022

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced it will be holding a Capital Markets Day for analysts, institutional investors and media on Wednesday 2 November 2022 at 9.30 am – 12.00 pm (GMT). The event, which will be chaired by CEO Yamin ‘Mo’ Khan, will provide a deeper insight into the Company’s end-to-end early clinical development services business, the human challenge trial market, and the benefits of human challenge to the Company’s

Open Orphan hVIVO

Open Orphan appoints Stephen Pinkerton as CFO

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (Ticker: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Stephen Pinkerton as Chief Financial Officer (“CFO”) and as an Executive Director, effective with immediate effect. Stephen will succeed Leo Toole who steps down from the Board and CFO role to pursue other interests. Leo will remain with the Company until 31 December 2022. Leo was appointed to the Board and as CFO in February 2020 following the acquisition of

hvivo plc

Open Orphan further positive data for FLU-v

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited’s broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1 Previous clinical studies have demonstrated that FLU-v induced increased antibody and cellular responses in vivo. This placebo-controlled study evaluated the ability of FLU-v to induce cellular effector functions and cross-reactivity (both measures of the immune response, with cross-reactivity being particularly

Interviews

Question & Answers

Analyst Notes & Comments

More Information

Latest Open Orphan plc News

Interviews

Questions & Answers

Broker Notes & Comments

Open Orphan plc share price

Fundamentals

Share this page

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.